Sec Form 3 Filing - Alloway Paul @ Homology Medicines, Inc. - 2022-03-02

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Alloway Paul 2. Issuer Name and Ticker or Trading Symbol Homology Medicines, Inc. [ FIXX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) See Remarks (Last) (First) (Middle) C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK 3. Date of Earliest Transaction (MM/DD/YY) 03/02/2022 (Street) BEDFORD, MA01730 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 10,226 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Employee Stock Option (Right to Buy) $ 12.66 ( 1 ) 05/05/2030 Common Stock 125,000 D Employee Stock Option (Right to Buy) $ 13.78 ( 2 ) 02/05/2031 Common Stock 79,000 D Employee Stock Option (Right to Buy) $ 2.71 ( 3 ) 02/24/2032 Common Stock 95,000 D Restricted Stock Unit $ 0 ( 4 ) ( 4 ) Common Stock 8,710 D Restricted Stock Unit $ 0 ( 5 ) ( 5 ) Common Stock 16,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Alloway Paul C/O HOMOLOGY MEDICINES, INC. ONE PATRIOTS PARK BEDFORD, MA01730 See Remarks Signatures /s/ W. Bradford Smith, Attorney-in-Fact for Paul Alloway 03/11/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The option vests as to 25% of the underlying shares on May 1, 2021 and in 36 substantially equal monthly installments thereafter. ( 2 )The option vests in 48 substantially equal monthly installments on the first day of each calendar month following January 1, 2021. ( 3 )The option vests in 48 substantially equal monthly installments on the first day of each calendar month following January 1, 2022. ( 4 )The restricted stock units will vest and settle as to approximately one half of the restricted stock units on each of January 1, 2023 and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date. ( 5 )The restricted stock units will vest and settle as to approximately one third of the restricted stock units on each of the first three anniversaries of January 1, 2022 so that such RSUs will become fully vested on January 1, 2025. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date.

Remarks: Chief Legal Officer and SecretaryExhibit 24 - Power of Attorney.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.